UNSPSC 51402201: Pagoclone

This classification denotes an anxiolytic with the molecular formula C23H22ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38VAG2SA33, chemically known as 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one but generally known as pagoclone, which bears US NIH Compound Identifier 131664. European Medicines Agency schedules Pagoclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09586MIG.

UNSPSC 51402201 Pagoclone is a Commodity code that does not align with the recent state and local contract opportunities posted against it. The code nominally describes a specific pharmaceutical product (pagoclone), but the three most recent solicitations under this code seek naloxone and drug deactivation systems, therapeutic pharmacy initiative capabilities, and generic multi-source pharmaceuticals with over-the-counter products — none of which are pagoclone. The mismatch suggests that either the code has been misapplied by issuing bodies to pharmaceutical procurements more broadly, or the opportunities are incorrectly tagged in the source system.

The issuing bodies span multiple state and local jurisdictions: Seminole County, Florida (county government); the Texas Health and Human Services Commission (state agency); and the Minnesota Multistate Cooperative Purchasing Alliance on behalf of participating state and local facilities including Oregon (cooperative purchasing vehicle). The most concrete recent opportunity is Seminole County's competitive bid (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas HHS Commission issued an exploratory Request for Information in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota MMCAP cooperative issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with contracts effective July 1, 2026. Given the lack of alignment between the code's nominal scope and the actual work being solicited, this code shows little relevant recent activity for firms focused on pagoclone-specific procurement.